Summary
BAY-g-5421 is an α-glucosidase-inhibitor which inhibits intestinal absorption of carbohydrates. In a double-blind cross over study 12 diabetics taking sulphonylureas and 12 insulin-treated diabetics were treated additionally with BAY-g-5421 or a placebo for two seven day periods. In the pretreatment period and on the 7th and 14th day of the treatment periods serial blood glucose profiles were measured. In comparison to placebo BAY-g-5421 significantly lowered the mean (140 versus 157 mg/dl) and the maximal (192 versus 230 mg/dl) blood glucose values and the integrated blood glucose response (3112 versus 3421 mg/dl · 24 h) in the sulphonylurea-treated group as well as in the insulin-treated group (mean blood glucose 161 versus 192 mg/dl, maximal blood glucose 238 versus 283 mg/dl, integrated blood glucose response 3109 versus 3857 mg/dl · 24 h). The amplitude of glycaemic excursions was significantly decreased only in the sulphonylurea-treated group (96 versus 129 mg/dl), but not in the insulin-treated diabetics. No influence on routine liver function, renal function or haematological tests was observed. Side effects included hypoglycaemia in 3 patients of the insulin-treated group and meteorism in both groups. BAY-g-5421 could be a useful additional treatment for diabetic patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Puls, W., Keup, U.: Influence of an α-amylase inhibitor (BAY-d-7791) on blood glucose, serum insulin, and NEFA in starch loading tests in rats, dogs, and man. Diabetologia9, 97–101 (1973)
Puls, W., Keup, U.: Metabolic studies with an amylase inhibitor in acute starch loading tests in rats and men and its influence on the amylase content of the pancreas. In: Recent advances in obesity research, I. Howard, A. (Ed.), pp. 391–393. London: Newman 1975
Keup, U., Puls, W.: Influence of an amylase inhibitor BAY-e-4609 on the conversion of orally applicated starch into total lipids of rat adipose tissue. In: Recent advances in obesity research, I. Howard, A. (Ed.), p. 412. London: Newman 1975
Puls, W., Keup, U.: Inhibition of sucrase by tris in rat and man, demonstrated by oral loading tests with sucrose. Metabolism24, 93–98 (1975)
Schmidt, D. D., Frommer, W., Junge, B., Müller, L., Wingender, W., Truscheit, E., Schäfer, D.: α-glucosidase inhibitors, new complex oligosaccharides of microbial origin. Naturwissenschaften64, 535 (1977)
Puls, W., Keup, U., Krause, H. P., Thomas, G., Hoffmeister, F.: Glucosidase inhibition, a new approach to the treatment of diabetes, obesity, and hyperlipoproteinämia. Naturwissenschaften64, 536 (1977)
Walton, R. J., Sherif, I. T., Noy, G. A., Alberti, K. G. M. M.: Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor. Br. Med. J.1979 I, 220–221
Caspary, W. F.: Sucrose malabsorption in man after ingestion of α-glucosidase inhibitor. Lancet1978 I, 1231–1233
Hillebrand, I.: Personal communication
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sachse, G., Willms, B. Effect of theα⁃ glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics. Diabetologia 17, 287–290 (1979). https://doi.org/10.1007/BF01235884
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01235884